Published in World J Surg Oncol on May 20, 2005
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol (2008) 3.34
Behavior of healthcare workers after injuries from sharp instruments. Trauma Mon (2013) 1.30
The prevalence of hepatitis B virus markers in a cohort of students in Bangui, Central African Republic. BMC Infect Dis (2010) 1.13
Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer (2010) 1.07
Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci (2011) 1.02
PTEN in liver diseases and cancer. World J Gastroenterol (2010) 0.97
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol (2011) 0.84
Implication of protein kinase R gene quantification in hepatitis C virus genotype 4 induced hepatocarcinogenesis. Diagn Pathol (2012) 0.83
Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. J Stud Alcohol Drugs (2011) 0.83
HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma. Onco Targets Ther (2014) 0.80
Epidemiology of hepatitis C: related hepatocellular carcinoma in Cameroon. Pan Afr Med J (2014) 0.78
Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol (2010) 0.78
Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. J Clin Transl Hepatol (2015) 0.78
Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies. BMC Cancer (2015) 0.78
Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line. Adv Biomed Res (2016) 0.76
Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients. ISRN Hepatol (2013) 0.76
Current imaging strategies of primary and secondary neoplasms of the liver. Semin Intervent Radiol (2006) 0.75
Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma. Cancer Med (2016) 0.75
Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience. ISRN Hepatol (2012) 0.75
Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model. Oncotarget (2016) 0.75
Hepatitis viruses exploitation of host DNA methyltransferases functions. Clin Exp Med (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci U S A (1978) 8.92
Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol (1991) 8.33
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 6.96
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science (1999) 6.21
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med (1997) 6.03
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol (2000) 5.76
Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol (1988) 5.75
Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med (1991) 5.69
Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med (1995) 5.55
HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (1991) 5.34
Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med (1993) 5.32
Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet (1995) 5.03
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology (2000) 4.97
Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology (1994) 4.77
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
Epidemiology of primary liver cancer. Semin Liver Dis (1999) 4.48
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology (1990) 4.43
Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science (1992) 4.42
Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol (2002) 4.22
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med (1976) 4.01
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell (1989) 3.60
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology (2000) 3.53
Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet (1989) 3.42
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology (2000) 3.42
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med (1996) 3.41
Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res (1989) 3.35
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology (1997) 3.10
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol (2002) 2.94
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94
National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology (1997) 2.89
Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med (2000) 2.67
A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer (1998) 2.64
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology (2001) 2.62
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology (1998) 2.62
Transcriptional trans-activating function of hepatitis B virus. J Virol (1987) 2.46
High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut (1999) 2.46
A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology (1993) 2.41
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol (1999) 2.38
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol (2001) 2.36
Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res (1989) 2.35
Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis (1990) 2.30
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25
Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst (1990) 2.23
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (1999) 2.16
Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol (1993) 2.16
The long-term pathological evolution of chronic hepatitis C. Hepatology (1996) 2.15
Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology (2002) 2.13
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med (1998) 2.01
Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol (1999) 1.96
Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology (2000) 1.96
Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med (1992) 1.92
Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology (2001) 1.91
Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med (1993) 1.89
Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A (1995) 1.87
Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol (1998) 1.84
Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology (1986) 1.84
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut (2000) 1.84
Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet (1990) 1.83
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.83
Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet (1995) 1.80
Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol (1996) 1.79
Screening for hepatocellular carcinoma. Hepatology (1998) 1.78
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol (2003) 1.74
Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol (2002) 1.74
Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology (1985) 1.73
The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature (1990) 1.69
The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer (1992) 1.68
Hepatocellular carcinoma: present status and future prospects. J Hepatol (2003) 1.66
Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology (2001) 1.65
Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology (2002) 1.64
Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol (1995) 1.63
The long-term course of chronic hepatitis B. Hepatology (1999) 1.63
Modeling the hepatitis C virus epidemic in France. Hepatology (1999) 1.61
The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol (1996) 1.60
Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology (1995) 1.57
Activation of hepatitis B virus S promoter by the viral large surface protein via induction of stress in the endoplasmic reticulum. J Virol (1997) 1.56
Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem (1997) 1.54
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet (2001) 1.52
Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology (1997) 1.52
Bacillus Calmette-Guérin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. Eur J Gastroenterol Hepatol (2004) 0.83
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. Obesity (Silver Spring) (2014) 0.77
Fine needle trucut biopsy in focal liver lesions: a reliable and safe method in identifying the malignant nature of liver lesions. Acta Gastroenterol Belg (2007) 0.75